Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Voyager Therapeutics (VYGR) Research & Development (2016 - 2025)

Voyager Therapeutics' Research & Development history spans 11 years, with the latest figure at $36.0 million for Q4 2025.

  • For Q4 2025, Research & Development rose 1.04% year-over-year to $36.0 million; the TTM value through Dec 2025 reached $134.7 million, up 5.74%, while the annual FY2025 figure was $134.7 million, 5.74% up from the prior year.
  • Research & Development for Q4 2025 was $36.0 million at Voyager Therapeutics, roughly flat from $35.9 million in the prior quarter.
  • Across five years, Research & Development topped out at $36.0 million in Q4 2025 and bottomed at $12.5 million in Q2 2022.
  • The 5-year median for Research & Development is $24.1 million (2021), against an average of $24.4 million.
  • The largest annual shift saw Research & Development plummeted 36.26% in 2021 before it soared 77.01% in 2023.
  • A 5-year view of Research & Development shows it stood at $14.0 million in 2021, then grew by 3.79% to $14.6 million in 2022, then skyrocketed by 77.01% to $25.8 million in 2023, then soared by 38.15% to $35.6 million in 2024, then grew by 1.04% to $36.0 million in 2025.
  • Per Business Quant, the three most recent readings for VYGR's Research & Development are $36.0 million (Q4 2025), $35.9 million (Q3 2025), and $31.3 million (Q2 2025).